WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 10 fonti

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - AstraZeneca (NYSE:AZN)

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.

Raccontata da

morningstar.com

eluniversal.com.mx

medpagetoday.com

biopharmadive.com

independent.co.uk

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo2 g fa

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - AstraZeneca (NYSE:AZN)

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.

Timeline cronologica

lunedì 8 giugno 2026·morningstar.com
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
lunedì 8 giugno 2026·statnews.com
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

3 g fa

AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push

AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.

Leggi questa versione → originale

statnews.com3 g fa

AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials

AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.

Leggi questa versione → originale

france24.com2 g fa

Encouraging trial results for AstraZeneca's new weight-loss pill

A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other GLP-1 oral drugs, trial results showed Monday.

Leggi questa versione → originale

independent.co.uk1 g fa

AstraZeneca daily pill shows promising weight loss results in trial

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be…

Leggi questa versione → originale

biopharmadive.com2 g fa

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.

Leggi questa versione → originale

lunedì 8 giugno 2026·

endpoints.news

AstraZeneca's obesity pill matches rivals in Phase 2, anchoring $5B franchise push

AstraZeneca's oral GLP-1 elecoglipron cut weight up to 10.5% in Phase 2, as AZ launches multiple Phase 3 trials targeting a $5B obesity franchise.

lunedì 8 giugno 2026·

eluniversal.com.mx

AstraZeneca se suma al mercado contra la obesidad, nueva pastilla da resultados alentadores en ensayo clínico

Especialistas consideran que el medicamento merece evaluaciones más amplias antes de solicitar su autorización

lunedì 8 giugno 2026·

lecho.be

AstraZeneca rentre dans la course aux comprimés anti-obésité avec des résultats "très compétitifs"

AstraZeneca publie des résultats prometteurs pour son traitement oral contre l’obésité, elecoglipron, ouvrant la voie à un nouvel entrant potentiel sur un marché dominé par Novo…

martedì 9 giugno 2026·

france24.com

Encouraging trial results for AstraZeneca's new weight-loss pill

A new pill developed by the British pharma firm AstraZeneca appears to help people lose a similar amount of weight to other GLP-1 oral drugs, trial results showed Monday.

martedì 9 giugno 2026·

medpagetoday.com

Oral Small-Molecule Elecoglipron Tackles Obesity and Diabetes

Investigational pill was well-tolerated and doesn't come with food or water restrictions

martedì 9 giugno 2026·

benzinga.com

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - AstraZeneca (NYSE:AZN)

AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.

mercoledì 10 giugno 2026·

biopharmadive.com

AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine

Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted…

mercoledì 10 giugno 2026·

independent.co.uk

AstraZeneca daily pill shows promising weight loss results in trial

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…